Therapy Areas: Oncology
Merck reports positive data from Keytruda phase three Keynote-181 oesophageal cancer trial
16 November 2018 - United States-based Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), significantly improved overall survival rate in the phase three Keynote-181 oesophageal cancer trial, i...
Harpoon Therapeutics Closes USD 70m Series C Financing
15 November 2018 - - US-based clinical-stage immunotherapy company Harpoon Therapeutics, Inc has closed a USD 70m Series C equity financing, the company said.

OrbiMed served as the lead n...
Farxiga Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial, According to AstraZeneca
15 November 2018 - - Anglo-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) has received positive full results from the DECLARE-TIMI 58 cardiovascular outcomes trial for Farxiga (dapagliflozin)...
Brooklyn ImmunoTherapeutics Presents Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer
15 November 2018 - - US-based biopharmaceutical company Brooklyn ImmunoTherapeutics presented the clinical results of IRX-2 therapy in resectable breast cancer and head and neck cancer that were prese...
Tikcro Technologies reports Q3 2018 financial results
15 November 2018 - Tikcro Technologies Ltd (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, reported yesterday its financial results for the third quarter ended ...
US Food and Drug Administration grants priority review to Roche's Tecentriq
15 November 2018 - The US Food and Drug Administration (FDA) has granted priority review to Switzerland-based Roche for its Tecentriq (atezolizumab) in combination with chemotherapy as the first-line ...
Related Headlines

Harpoon Therapeutics Launches ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets

Personalis Launches ImmunoID NeXT, a Platform Providing Characterization of a Tumor and Its Microenvironment from a Single Sample

FDA Approves Merck's Keytruda for the Treatment of Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

F1 Oncology plans acquisition of strategic CAR-T assets for treating solid tumour malignancies

OneOncology appoints Erich Mounce as first COO

Gilead Touts Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis at The Liver Meeting 2018

AstraZeneca signs agreement to divest US rights of Synagis to Sobi for USD1.5bn

Agenus names new director

CRISPR Therapeutics expands clinical and commercial license agreement with MaxCyte

Alpine Immune Sciences Advances Oncology Programmes with New ALPN-202 Preclinical Data

Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs

Global Cervical Cancer Diagnostic Testing Market to Grow at a CAGR of Over 6% by 2023, According to Technavio

New Data from Investigational Study of Lenvima and Keytruda Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd annual meeting

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

Harpoon Therapeutics completes USD70m series C equity financing